DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF. et al.
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
PLoS Med 2005;
2: e73
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.